Tempest Therapeutics, Inc. (TPST) company profile

Tempest Therapeutics is a clinical-stage biotechnology company that develops targeted therapies for oncology and immunology indications. The company focuses on advancing cell therapy and small-molecule product candidates. Its primary cell therapy programs include TPST-2003, an autologous dual-targeting CAR-T therapy evaluated for relapsed or refractory multiple myeloma and POEMS syndrome, alongside additional autologous, allogeneic, and in vivo CAR-T candidates targeting conditions like solid tumors and lupus. Tempest also advances two clinical-stage small-molecule candidates, amezalpat, an oral PPARα antagonist evaluated for hepatocellular carcinoma, and TPST-1495, an oral dual antagonist of EP2 and EP4 receptors evaluated for familial adenomatous polyposis. Its therapies are designed for patients facing high unmet medical needs in oncology and related fields.

The company conducts clinical and preclinical studies across international territories, with trials underway in China and planned developments in the United States. Its asset licenses cover global territories excluding Greater China, India, Russia, and Turkey. The provided text does not state the company's headquarters or specific facility counts.

Summary of the business section of Tempest Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 1, 2026, we had four employees, including four full-time employees and three holding Ph.D., MBA and/or M.S.”